Capital International, Inc. Neurocrine Biosciences Inc Transaction History

Capital International, Inc.

$7.83 Billion
Q1 2025

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $1.35 Million - $1.76 Million	-18,566 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $21.7 Million - $28.9 Million	-272,138 Reduced 93.61%	18,566 $1.58 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $4.03 Million - $4.63 Million	-46,763 Reduced 13.86%	290,704 $27.9 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $1.78 Million - $2.04 Million	-19,907 Reduced 5.57%	337,467 $32.8 Million
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $3.56 Million - $4.85 Million	-40,605 Reduced 10.2%	357,374 $34.8 Million
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $693,107 - $863,931	-7,975 Reduced 1.96%	397,979 $38.1 Million
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $8.03 Million - $11.3 Million	-83,510 Reduced 17.06%	405,954 $39 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $601,416 - $921,384	7,068 Added 1.47%	489,464 $59.7 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $3.04 Million - $4.6 Million	-40,419 Reduced 7.73%	482,396 $41.8 Million
Q4 2019 Feb 18, 2020	SELL	$86.8 - $118.57 $691,709 - $944,884	-7,969 Reduced 1.5%	522,815 $56.2 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $42.8 Million - $51.8 Million	510,286 Added 2489.44%	530,784 $47.8 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $97,379 - $123,031	1,348 Added 7.04%	20,498 $1.73 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $242,585 - $320,355	3,500 Added 22.36%	19,150 $1.69 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $1.07 Million - $1.95 Million	15,650 New	15,650 $1.12 Million

Others Institutions Holding NBIX

# of Institutions

650

Shares Held

97.2M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital International, Inc. with notifications on news.

Account